Innate Pharma announces Phase II results from monalizumab and cetuximab combination in head and neck cancer at the ESMO 2018 Congress
(WorldNews Europe)

Confirmation of previously reported response rate and new data on durability of response reinforces the potential anti-tumor activity of the monalizumab cetuximab combination Clinical program advances with an expansion cohort in patients previously treated with PD-1/L1 therapies Management to host KOL call Monday, October 22, 4pm CEST (10am ET) Innate Pharma SA (the `Company` - Euronext Paris: FR0010331421 - IPH), today announced updated data from the Phase II trial evaluating the safety and efficacy of the combination of monalizumab and cetuximab (anti-EGFR) in previously treated patients with recurrent and/or metastatic squamous cell carcinoma of the head & neck (R/M SCCHN). The data will...